Its high-tech bioprocessing equipment is being loaned to the New Zealand Covid-19 Vaccine Corporation.
Corporation chief executive Dr Robert Feldman says a vaccine couldn't be made without this type of technology.
He says they're working on a biobead vaccine, from components of the SARS virus.
Feldman says they're gearing towards making the first production run for tests ahead of a clinical trial, which is slated for early 2022.
